Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02879162
Title Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

osteosarcoma

ovarian clear cell carcinoma

anal canal squamous cell carcinoma

salivary gland carcinoma

sarcoma

mucosal melanoma

acral lentiginous melanoma

carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult | child | senior
Covered Countries CAN


No variant requirements are available.